Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth

Munguia, Audelia; Ota, Takayo; Miest, Tanner; Russell, Stephen J.

doi:10.1038/gt.2008.45

Cited by 52 publications

(38 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have explored the use of virusinfected cells as carriers to protect and transport the virus to sites of tumor growth (48)(49)(50)(51) or synthetic polymers to coat and protect the virus from antibody neutralization (39,52) or have employed G protein evolution strategies to generate neutralization-resistant variants of VSV G (53). However, each of these approaches has its limitations.…”

Section: Discussionmentioning

confidence: 99%

Vesiculovirus Neutralization by Natural IgM and Complement

Tesfay

Ammayappan

Federspiel

et al. 2014

J Virol

View full text Add to dashboard Cite

Because of its very low human seroprevalence, vesicular stomatitis virus (VSV) has promise as a systemic oncolytic agent for human cancer therapy. However, as demonstrated in this report, the VSV infectious titer drops by 4 log units during the first hour of exposure to nonimmune human serum. This neutralization occurs relatively slowly and is mediated by the concerted actions of natural IgM and complement. Maraba virus, whose G protein is about 80% homologous to that of VSV, is relatively resistant to the neutralizing activity of nonimmune human serum. We therefore constructed and rescued a recombinant VSV whose G gene was replaced by the corresponding gene from Maraba virus. Comparison of the parental VSV and VSV with Maraba G substituted revealed nearly identical host range properties and replication kinetics on a panel of tumor cell lines. Moreover, in contrast to the parental VSV, the VSV with Maraba G substituted was resistant to nonimmune human serum. Overall, our data suggest that VSV with Maraba G substituted should be further investigated as a candidate for human systemic oncolytic virotherapy applications. IMPORTANCEOncolytic virotherapy is a promising approach for the treatment of disseminated cancers, but antibody neutralization of circulating oncolytic virus particles remains a formidable barrier. In this work, we developed a pseudotyped vesicular stomatitis virus (VSV) with a glycoprotein of Maraba virus, a closely related but serologically distinct member of the family Rhabdoviridae, which demonstrated greatly diminished susceptibility to both nonimmune and VSV-immune serum neutralization. VSV with Maraba G substituted or lentiviral vectors should therefore be further investigated as candidates for human systemic oncolytic virotherapy and gene therapy applications.

show abstract

Section: Discussionmentioning

confidence: 99%

Vesiculovirus Neutralization by Natural IgM and Complement

Tesfay

Ammayappan

Federspiel

et al. 2014

J Virol

View full text Add to dashboard Cite

show abstract

“…Ongoing preclinical studies have shown that using cellular virus-delivery vehicles (i.e. mesenchymal progenitor cells, monocytes, T cells) can facilitate viral delivery to tumor cells (Munguia et al, 2008;Russell and Peng, 2008;Willmon et al, 2009). Irradiated 5TGM1 myeloma cells transfected with VSV-GFP have been shown to deliver VSV to sites of myeloma tumor growth in an orthotopic human myeloma model (Munguia et al, 2008).…”

Section: Radiovirotherapymentioning

confidence: 99%

“…mesenchymal progenitor cells, monocytes, T cells) can facilitate viral delivery to tumor cells (Munguia et al, 2008;Russell and Peng, 2008;Willmon et al, 2009). Irradiated 5TGM1 myeloma cells transfected with VSV-GFP have been shown to deliver VSV to sites of myeloma tumor growth in an orthotopic human myeloma model (Munguia et al, 2008). Since intravenous delivery of radiotargeted gene therapy is prerequisite for targeting systemic myeloma tumor sites, selection of the optimal cell carrier for radiovirotherapy is expected to improve the tumor remission rate in MM.…”

Section: Radiovirotherapymentioning

confidence: 99%

Enhancing Therapeutic Radiation Responses in Multiple Myeloma

Salem¹,

Goel²

2012

Modern Practices in Radiation Therapy

View full text Add to dashboard Cite

“…After 20-30 days, small (4-5 mm) or large (8-10 mm) tumors were established. Then 100 μl of AdE3-IAI.3B (1x10 10 PFU, plaque forming units), AdE3 (1x10 10 PFU), Ad-ß-gal (1x10 10 PFU), medium alone, or A549 carrier cells infected with AdE3-IAI.3B at 200 MOI (multiplicity of infection) were injected intratumorally on days 0, 1, 2, 3, 4 and 5. The tumors were measured every 2 days with calipers to determine two perpendicular diameters.…”

Section: Inhibition Of Subcutaneous Tumor Growth In Vivomentioning

confidence: 99%

“…Many studies of oncolytic vector-infected carrier cells have been reported, including intraperitoneal injection of PA-1 ovarian carcinoma cells infected with an oncolytic HSV-1 to treat intraperitoneal ovarian carcinoma xenografts (7), intravenous injection of MDA-MG-231 breast carcinoma cells infected with wild-type adenovirus to treat lung metastatic foci of breast carcinoma xenografts (8), intravenous injection of mesenchymal stem cells infected with oncolytic adenovirus to treat lung and breast tumor xenografts (9), intravenous injection of myeloma cells infected with oncolytic measles, vaccinia, vesicular stomatitis virus, and coxsackievirus A21 to treat orthotopic myeloma xenografts (10), intravenous injection of cytokine-induced killer cells infected with modified vaccinia virus to treat intraperitoneal ovarian tumors and subcutaneous breast tumors in syngeneic mice (11), intravenous injection of rat hepatoma cells infected with oncolytic parvovirus to treat lung metastatic foci of syngeneic rat hepatoma tumors (12), intravenous injection of CT26 tumor cells infected with oncolytic vesicular stomatitis virus to treat lung metastatic foci of syngeneic mouse CT26 colon tumors (13), intravenous injection of autologous CD8 + lymphocytes infected with oncolytic vesicular stomatitis virus to treat lymphnode metastatic foci of syngeneic mouse melanoma tumors (14), and intratumoral injection of A549 tumor cells infected with oncolytic adenovirus to treat syngeneic mouse ovarian tumors (15). These carrier cell treatments have yielded significant antitumor effects in syngeneic and non-syngeneic mouse tumors and completely overcome the inhibition of virus infection by antiviral antibody production (13,15).…”

Section: Introductionmentioning

confidence: 99%

Gene therapy for oral squamous cell carcinoma with IAI.3B promoter-driven oncolytic adenovirus-infected carrier cells

Zhang

Hamada

Hyodo³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. Although replication-competent oncolytic viral vectors have been developed to improve antitumor activity, the generation of high titers of neutralizing antibodies inhibits repetitive viral infection. Many studies have reported that oncolytic virus-infected carrier cells can overcome this viral induced immunogenicity. However, the effects of oncolytic virus-infected carrier cells in human oral squamous cell carcinoma (OSCC) have not yet been examined. In the present study, simulating the clinical trial, we examined the antitumor activity of carrier cells infected with oncolytic adenovirus AdE3-IAI.3B in human OSCC. IAI.3B was highly activated in OSCC cells but not in normal cells. AdE3-IAI.3B killed OSCC cells in vitro but not normal cells. AdE3-IAI.3B-infected A549 carrier cells eradicated OSCC GFP-SAS tumors in nude mice. Anti-adenovirus neutralizing antibodies completely blocked the antitumor effect of AdE3-IAI.3B but did not block that of carrier cells. After the induction of anti-adenoviral CTL responses by immunization of adenovirus, administration of carrier cells induced complete regression of murine squamous cell carcinoma SCC7 tumors. Adenovirus-GM-CSF augmented the antitumor effect of carrier cells. The IAI.3B-driven oncolytic adenovirus-infected carrier cell system might prove useful in the treatment of OSCC and clinical trials of it should be conducted in the near future.

show abstract

Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth

Cited by 52 publications

References 84 publications

Vesiculovirus Neutralization by Natural IgM and Complement

Vesiculovirus Neutralization by Natural IgM and Complement

Enhancing Therapeutic Radiation Responses in Multiple Myeloma

Gene therapy for oral squamous cell carcinoma with IAI.3B promoter-driven oncolytic adenovirus-infected carrier cells

Contact Info

Product

Resources

About